Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 19.13 GBp
Change Today +0.125 / 0.66%
Volume 280.2K
PRM On Other Exchanges
As of 11:35 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

proteome sciences plc (PRM) Snapshot

19.25 GBp
Previous Close
19.00 GBp
Day High
19.75 GBp
Day Low
19.00 GBp
52 Week High
09/25/14 - 41.50 GBp
52 Week Low
04/1/15 - 18.50 GBp
Market Cap
Average Volume 10 Days
-0.02 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for PROTEOME SCIENCES PLC (PRM)

Related News

No related news articles were found.

proteome sciences plc (PRM) Related Businessweek News

No Related Businessweek News Found

proteome sciences plc (PRM) Details

Proteome Sciences plc, a life sciences company, engages in the research and development of biomarkers. The company delivers content for personalized medicine in the areas of biomarker services, biomarker assays, isobaric and isotopic reagents, and proprietary biomarkers. It offers PS Biomarker Services, a biomarker outsourcing solution that provides integrated proteomic services for biomarker discovery, validation, and measurement in clinical trials and in vitro diagnostics. The company develops various proprietary biomarkers for a range of human diseases, including CNS disorders comprising Alzheimer’s, Huntington’s, stroke, traumatic brain injury, TSE’s, and pain; oncology consisting of lung, breast, esophageal, colorectal cancers, and neuroblastoma; and organ transplant rejection, such as renal and cardiac diseases. In addition, it offers protein tags and assays for spectrometry analysis; develops isobaric and isotopic reagents under the Tandem Mass Tag brand. Further, the company’s biomarker services include proteomics and peptidomics. Further, the company provides proprietary technologies for protein and peptide biomarker discovery, validation, and assay development. It serves pharmaceutical and biotechnology companies, and academia clients in the United Kingdom, Germany, and the United States. Proteome Sciences plc was incorporated in 1993 and is headquartered in Cobham, the United Kingdom.

36 Employees
Last Reported Date: 06/23/15
Founded in 1993

proteome sciences plc (PRM) Top Compensated Officers

Executive Chairman and Chief Executive
Total Annual Compensation: 288.5K GBP
Finance Director, Company Secretary and Execu...
Total Annual Compensation: 47.1K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 140.0K GBP
Compensation as of Fiscal Year 2014.

proteome sciences plc (PRM) Key Developments

Proteome Sciences plc Reports Unaudited Consolidated Earnings Results for the Year Ended December 31, 2014

Proteome Sciences PLC reported unaudited consolidated earnings results for the year ended December 31, 2014. For the period, the company reported revenue and other income of £1,560,715 against £2,136,681 a year ago. Operating loss was £3,993,518 against £3,372,515 a year ago. Loss before taxation was £4,227,297 against £3,596,188 a year ago. Loss for the period from continuing operations attributed to shareholders of the company was £3,566,481 against £3,149,159 a year ago. Loss for the period attributed to shareholders of the company was £3,566,481 or 1.69 pence per basic and diluted share against £3,149,159 or 1.62 pence per basic and diluted share a year ago. Net cash outflow from operating activities was £3,269,799 against £2,766,987 a year ago. Purchases of property, plant and equipment were £155,289 against £9,202 a year ago.

Proteome Sciences plc Announces Management Changes

Proteome Sciences plc announced that Mr. James Malthouse has retired as a director of the company and as Company Secretary. Mr. Geoffrey Ellis, the Finance Director, has been appointed as Company Secretary.

Proteome Sciences plc Appoints Martin Diggle as Non-Executive Director

The board of Proteome Sciences plc announced the appointment of Mr. Martin Diggle as Non-Executive Director with immediate effect. Mr. Diggle, 52, has worked in finance for over 30 years. He was a director and partner of UBS/Brunswick in Russia until 2003, following which he joined Vulpes Investment Management, where he is currently a director and partner. Mr. Diggle is currently a Non-Executive Director of Oxford Biomedica plc and Chronos Therapeutics Limited.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRM:LN 19.13 GBp +0.125

PRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRM.
View Industry Companies

Industry Analysis


Industry Average

Valuation PRM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTEOME SCIENCES PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at